Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Immune checkpoint inhibitor products come under biologic therapeutic products. Biologic manufacturers require similar kind of approvals such as drugs from the U.S. Food & Drug Administration prior to bringing the product into market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Initiatives undertaken by the governments include funding is expected to drive growth of the immune checkpoint inhibitors market. For instance, in 2021, National Institutes of Health partnered with 11 leading biopharmaceutical companies such as AbbVie and Amgen, Inc. to accelerate development of new immunotherapies.
Market Dynamics
Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.
Key features of the study:
This report provides in-depth analysis of Global Immune Checkpoint Inhibitors Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the Global Immune Checkpoint Inhibitors Market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Global Immune Checkpoint Inhibitors Market
Detailed Segmentation:
Global Immune Checkpoint Inhibitors Market, By Drug Class:
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
Global Immune Checkpoint Inhibitors Market, By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Immune Checkpoint Inhibitors Market, By Geography:
North America
By Drug Class
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Russia
Spain
Rest of Europe
Asia Pacific
By Drug Class
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
By Drug Class
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of LATAM
Middle East
By Drug Class
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Programmed Death Receptor-1 (PD-1) Inhibitors
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Others
Programmed Death-Ligand 1 (PD-L1) Inhibitors
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
CTL-4 Checkpoint Inhibitor
Ipilimumab (Yervoy)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
Lymphocyte-Activation Gene 3 Inhibitors
By Cancer Type:
Lung Cancer
Head & Neck Cancer
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
Blood Cancer (Lymphoma)
Bladder Cancer (Urothelial Carcinoma)
Renal/Kidney Cancer
Colorectal Cancer
Breast Cancer
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
North Africa
Central Africa
South Africa
Company Profiles
Bristol-Myers Squibb Company*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Merck & Co., Inc.
F. Hoffmann-La Roche AG
AstraZeneca Plc
Novartis International AG
ImmunOs Therapeutics AG
Immutep Ltd.
NewLink Genetics Corporation
Ono Pharmaceutical Co., Ltd.
Pfizer, Inc.
“*” marked represents similar segmentation in other categories in the respective section.